{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:19:53Z","timestamp":1778260793446,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.amjcard.2017.05.013","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T02:00:23Z","timestamp":1496196023000},"page":"S28-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"S","title":["Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms"],"prefix":"10.1016","volume":"120","author":[{"given":"Bart","family":"Staels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.05.013_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2017.05.013_bib3","first-page":"S17","article-title":"Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes","volume":"120","author":"L\u00fcscher","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.amjcard.2017.05.013_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrcardio.2016.35","article-title":"Heart failure: SGLT2 inhibitors and heart failure\u2014clinical implications","volume":"13","author":"Raz","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2017.05.013_bib7","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.amjcard.2017.05.012","article-title":"EMPA-REG OUTCOME: the nephrologist's point of view","volume":"120","author":"Wanner","year":"2017","journal-title":"Am J Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.amjcard.2017.05.013_bib8","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.amjcard.2017.05.013_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjcard.2017.05.013_bib10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.amjcard.2017.05.013_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2017.05.013_bib12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.05.013_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999","volume":"16","author":"Foley","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ki.2013.396","article-title":"Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes","volume":"85","author":"Wang","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2017.05.013_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: effects on the cardiovascular system","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2017.05.013_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/gft209","article-title":"Haemostasis in chronic kidney disease","volume":"29","author":"Lutz","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.amjcard.2017.05.013_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diabet.2015.12.005","article-title":"Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjcard.2017.05.013_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2017.05.013_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","article-title":"The EMPA-REG study: what has it told us? A diabetologist's perspective","volume":"30","author":"DeFronzo","year":"2016","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.amjcard.2017.05.013_bib23","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.amjcard.2017.05.013_bib25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00125-012-2817-5","article-title":"Revisiting the links between glycaemia, diabetes and cardiovascular disease","volume":"56","author":"Sattar","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2017.05.013_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.05.013_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2017.05.013_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2337\/dc08-0025","article-title":"Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study","volume":"31","author":"Fox","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3810\/pgm.2013.05.2667","article-title":"Effects of dapagliflozin on cardiovascular risk factors","volume":"125","author":"Ptaszynska","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib31","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.amjcard.2017.05.013_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.ajkd.2014.04.024","article-title":"Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002","volume":"64","author":"Odden","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2017.05.013_bib34","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/nutd.2014.40","article-title":"Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin","volume":"4","author":"Haas","year":"2014","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.amjcard.2017.05.013_bib35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3810\/pgm.2012.11.2615","article-title":"Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae","volume":"124","author":"Campos","year":"2012","journal-title":"Postgrad Med"},{"issue":"9","key":"10.1016\/j.amjcard.2017.05.013_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2017.05.013_bib37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2013.11.005","article-title":"O-GlcNAc and the cardiovascular system","volume":"142","author":"Dassanayaka","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2017.05.013_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4093\/kdj.2010.34.4.211","article-title":"O-GlcNAc modification: friend or foe in diabetic cardiovascular disease","volume":"34","author":"Karunakaran","year":"2010","journal-title":"Korean Diabetes J"},{"key":"10.1016\/j.amjcard.2017.05.013_bib39","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","article-title":"Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients","volume":"130","author":"Montaigne","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.05.013_bib40","first-page":"A286","article-title":"Empagliflozin improves beta-cell function measured with the hyperglycemic clamp in T2DM","volume":"65","author":"Al Jobori","year":"2016","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.amjcard.2017.05.013_bib41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2017.05.013_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.amjcard.2017.05.013_bib43","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib44","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2017.05.013_bib45","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.amjcard.2017.05.013_bib47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11883-013-0314-z","article-title":"Metformin therapy in diabetes: the role of cardioprotection","volume":"15","author":"El Messaoudi","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2017.05.013_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.05.013_bib49","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2017.05.013_bib50","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","article-title":"Diabetes mellitus and heart failure","volume":"120","author":"Lehrke","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib51","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.05.013_bib52","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.12475","article-title":"Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy","volume":"171","author":"Fillmore","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib54","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure","volume":"133","author":"Bedi","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjcard.2017.05.013_bib55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jdiacomp.2016.02.015","article-title":"EMPA-REG: glucose excretion and lipid mobilization - not storage - saves lives","volume":"30","author":"Jorgensen","year":"2016","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.amjcard.2017.05.013_bib56","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.116.022141","article-title":"Failing heart and starving brain: ketone bodies to the rescue","volume":"134","author":"Taegtmeyer","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.05.013_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin's fuel hypothesis: not so soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.amjcard.2017.05.013_bib59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diabres.2014.08.009","article-title":"Beta-hydroxybutyrate: much more than a metabolite","volume":"106","author":"Newman","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.amjcard.2017.05.013_bib60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","article-title":"Ketone bodies as signaling metabolites","volume":"25","author":"Newman","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2017.05.013_bib61","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuroscience.2006.11.065","article-title":"Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation","volume":"145","author":"Maalouf","year":"2007","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.amjcard.2017.05.013_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2007.12.029","article-title":"Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions","volume":"211","author":"Haces","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2016","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.amjcard.2017.05.013_bib64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"42","key":"10.1016\/j.amjcard.2017.05.013_bib65","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","volume":"37","author":"Marx","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.05.013_bib66","author":"Nainggolan"},{"key":"10.1016\/j.amjcard.2017.05.013_bib67","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Sarafidis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib68","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib69","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.amjcard.2017.05.013_bib71","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2016.05.006","article-title":"Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.amjcard.2017.05.013_bib72","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.05.013_bib73","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.05.013_bib74","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2017.05.013_bib75","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Fischereder","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib76","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.amjcard.2017.05.013_bib77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-016-0440-3","article-title":"Glucagon and heart\u00a0in\u00a0type 2 diabetes: new perspectives","volume":"15","author":"Ceriello","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib78","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/en.2011-1979","article-title":"Minireview: glucagon in stress and energy homeostasis","volume":"153","author":"Jones","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjcard.2017.05.013_bib79","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib80","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2017.05.013_bib81","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.amjcard.2017.05.013_bib82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MNH.0000000000000199","article-title":"Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension","volume":"25","author":"Tikkanen","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjcard.2017.05.013_bib83","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2017.05.013_bib85","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.05.013_bib86","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of\u00a0tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.amjcard.2017.05.013_bib87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejheart.2007.10.008","article-title":"Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit","volume":"10","author":"Lip\u0161ic","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2017.05.013_bib88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2017.05.013_bib89","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.05.013_bib90","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917308032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917308032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T20:01:54Z","timestamp":1659038514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917308032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0002914917308032"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.013","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}